Predicting favourable prognosis of urothelial carcinoma: Gene expression and genome profiling

Current Opinion in Urology

Volumn 19, Issue 5, 2009, Pages 516-521

  Van Der Kwast, Theodorus H ^a   Bapat, Bharati ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bladder cancer; CDNA profiling; Epigenetics; Genomics; Methylation; MicroRNA; Molecular pathways

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; MICRORNA;

BLADDER CARCINOGENESIS; CANCER STAGING; DNA METHYLATION; DNA MICROARRAY; EPIGENETICS; FGFR3 GENE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE; URINARY TRACT CARCINOMA; UROTHELIUM;

CARCINOMA; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 68949170824     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832eb45f     Document Type: Review

References (39)

1. Ørntoft TF, Zieger K, Dyrskjøt L. Recent developments in molecular profiling of bladder cancer. Curr Opin Urol 2006; 16:377-381. (Pubitemid 44231716)
2. Dyrskjøt L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in nonmuscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007; 13:3545-3551.
3. Van der Kwast TH. How to combine the molecular profile with the clinico-pathological profile of urothelial neoplastic lesions. Scand J Urol Nephrol 2008; 42 (S218):175-184.
4. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001; 158:1955-1959.
5. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63:8108-8112.
6. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54:784-788.
7. Chow NH, Cairns P, Eisenberger CF, et al. Papillary urothelial hyperplasia is a clonal precursors to papillary transitional cell bladder cancer. Int J Cancer 2000; 89:514-518.
8. Obermann EC, Junker K, Stoehr R, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003; 199:50-57.
9. Van Oers JM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006; 119:1212-1215.
10. Lopez-Beltran A, Alvarez-Kindelan J, Luque RJ, et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary noninvasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol 2008; 215:263-272.
11. Otto W, Denzinger S, Bertz S, et al. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in bladder cancer patients. Int J Cancer (In press).
12. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62:809-818.
13. Hopman AH, Kamps MA, Speel EJ, et al. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002; 161:1119-1125.
14. Van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21:1912-1921.
15. Zieger K, Dyrskjøt L, Wiuf C, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005; 11:7709-7719.
16. Hernandez S, Lopez-Knowles E, Lloreta J, etal. FGFR3 andTp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 2005; 11:5444-5450.
17. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213:91-98.
18. López-Knowles E, Hernández S, Kogevinas M, et al., EPICURO Study Investigators. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006; 12 (20 Pt 1):6029-6036.
19. Koed K, Wiuf C, Christensen LL, et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005; 65:34-45.
20. Van der Aa MN, van Leenders GJ, Steyerberg EW, et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 2005; 36:981-986.
21. Knowles MA. Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol 2008; 42 (S218):116-130.
22. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11 (19 Pt 1):7012-7022.
23. Dyrskjøt L, Kruhøffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64:4040-4048.
24. Dyrskjøt L. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33:90-96.
25. Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006; 25:2685-2696.
26. Rosser CJ, Liu L, Sun Y, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009; 18:444-453.
27. Als AB, Dyrskjøt L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13: 4407-4414.
28. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19:187-191.
29. Veerla S, Panagopoulos I, Jin Y, et al. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer 2008; 47:368-378.
30. Aleman A, Adrien L, Lopez-Serra L, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008; 98:466-473.
31. Cho WCS. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6:60.
32. Brait M, Begum S, Carvalho AL, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:2786-2794.
33. Dhawan D, Hamdy FC, Rehman I, etal. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006; 209:336-343.
34. Salem C, Liang G, Tsai YC, etal. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000; 60:2473-2476.
35. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23:2903-2910.
36. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61:8659-8663.
37. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13:2046-2053.
38. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009; 124:2236-2242.
39. Dyrskjøt L, Ostenfeld MS, Bramsen JB, etal. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009; 69:4851-4860.